These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21078948)

  • 41. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
    Teixeira C; Serradji N; Maurel F; Barbault F
    Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
    Wang T; Zhang Z; Wallace OB; Deshpande M; Fang H; Yang Z; Zadjura LM; Tweedie DL; Huang S; Zhao F; Ranadive S; Robinson BS; Gong YF; Ricarrdi K; Spicer TP; Deminie C; Rose R; Wang HG; Blair WS; Shi PY; Lin PF; Colonno RJ; Meanwell NA
    J Med Chem; 2003 Sep; 46(20):4236-9. PubMed ID: 13678401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
    Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
    Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.
    Wang T; Kadow JF; Meanwell NA; Krystal M
    Adv Exp Med Biol; 2022; 1366():45-64. PubMed ID: 35412134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
    Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
    J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.
    Liu T; Huang B; Zhan P; De Clercq E; Liu X
    Eur J Med Chem; 2014 Oct; 86():481-90. PubMed ID: 25203778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
    Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
    J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
    J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
    Wei X; Decker JM; Liu H; Zhang Z; Arani RB; Kilby JM; Saag MS; Wu X; Shaw GM; Kappes JC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1896-905. PubMed ID: 12019106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.
    Vermeire K; Schols D
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
    Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
    Swidorski JJ; Liu Z; Yin Z; Wang T; Carini DJ; Rahematpura S; Zheng M; Johnson K; Zhang S; Lin PF; Parker DD; Li W; Meanwell NA; Hamann LG; Regueiro-Ren A
    Bioorg Med Chem Lett; 2016 Jan; 26(1):160-7. PubMed ID: 26584882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.